	US 12,274,830 B2
	Nitric oxide inhalation therapy for infants with bronchiolitis
Yossef Av-Gay, Vancouver (CA); David Greenberg, Omer (IL); and Asher Tal, Meytar (IL)
Assigned to BEYOND AIR LTD, Rehovot (IL)
Filed by BEYOND AIR LTD, Rehovot (IL)
Filed on Jan. 27, 2021, as Appl. No. 17/159,458.
Application 17/159,458 is a continuation of application No. 16/787,921, filed on Feb. 11, 2020.
Application 16/787,921 is a continuation of application No. 15/758,108, abandoned, previously published as PCT/IB2016/001447, filed on Sep. 9, 2016.
Claims priority of provisional application 62/220,321, filed on Sep. 18, 2015.
Claims priority of provisional application 62/215,809, filed on Sep. 9, 2015.
Prior Publication US 2021/0205565 A1, Jul. 8, 2021
Int. Cl. A61M 16/12 (2006.01); A61K 33/00 (2006.01); A61K 45/06 (2006.01); A61P 31/00 (2006.01); A61B 5/083 (2006.01); A61B 5/145 (2006.01)

CPC A61M 16/12 (2013.01) [A61K 33/00 (2013.01); A61K 45/06 (2013.01); A61P 31/00 (2018.01); A61B 5/0833 (2013.01); A61B 5/14507 (2013.01); A61M 2202/0007 (2013.01); A61M 2202/0275 (2013.01)]

15 Claims

1. A method of delivering gaseous nitric oxide (gNO) to a patient in need thereof, the method comprising administering, by intermittent inhalation, 200 ppm to 320 ppm gNO for 10 to 45 minutes 2 to 5 times per day to provide a therapeutic amount of gNO wherein the therapeutic amount is a nitric oxide-load (NO load) of 300 ppm-hrs to 900 ppm-hrs of gNO per day over a period of at least 14 days; wherein the patient has a condition associated with a pathogenic microorganism; wherein the pathogenic microorganism is non-tuberculous mycobacteria (NTM); and wherein the therapeutic amount of gNO results in a reduction of a bacterial load of the NTM.